Supernus Pharmaceuticals, Inc. (SUPN) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company is headquartered in Rockville, MD, United States. The current CEO is Jack A. Khattar.
SUPN has IPO date of 2012-05-01, 674 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $2.89B.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Rockville, Maryland, specializing in the development and commercialization of central nervous system (CNS) disease treatments. The company's commercial portfolio includes Trokendi XR and Oxtellar XR for epilepsy and migraine management, Qelbree for pediatric ADHD, and several Parkinson's disease treatments including APOKYN, XADAGO, GOCOVRI, and Osmolex ER, as well as MYOBLOC for cervical dystonia and sialorrhea. Beyond its marketed products, Supernus maintains a pipeline of investigational candidates at various clinical stages, including SPN-830 for Parkinson's disease, SPN-817 for severe epilepsy, and SPN-820 for treatment-resistant depression. The company distributes its products through pharmaceutical wholesalers, specialty pharmacies, and distributors across the United States.
